Trial Profile

Phase 1, Multicenter, First-in-Human Dose Escalation Study of ALMB-0168 Administered IV as a Single Agent to Patients with Malignant Bone Disease

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 18 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ALMB-0168 (Primary)
Indications Advanced breast cancer; Bone metastases; Osteosarcoma; Prostate cancer; Solid tumours
Focus Adverse reactions; First in man

Most Recent Events

28 Jan 2022 Actual date of last participant enrolled is 6/01/2021 according to Australian New Zealand Clinical Trials Registry record.
28 Jan 2022 Status changed from recruiting to discontinued.
04 Mar 2021 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com